Navigation Links
Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample

By Amanda Gardner
HealthDay Reporter

TUESDAY, Jan. 4 (HealthDay News) -- A collaborative effort involving U.S. scientists and private companies is looking into a test that could find even one stray cancer cell among the millions of cells in a given blood sample.

The hope is that one day such a test, given soon after a treatment is started, could indicate whether the therapy is working or not. It might even indicate beforehand which treatment would be most effective.

The test, and others like it under development, relies on circulating tumor cells (CTCs) -- cancer cells that have detached from the main tumor and are traveling to other parts of the body.

Other versions of tests aimed at spotting CTCs are already in the works. For example, a few years ago, researchers at Veridex LLC, a Johnson & Johnson company, developed a technology called CellSearch, which counts the number of stray cancer cells in blood. However, that test didn't allow scientists to trap whole cells and analyze them.

And at Massachusetts General Hospital, researchers have developed a type of microchip with a surface covered with antibodies that are designed to stick to tumor cells. As blood passes over the chip, tumor cells separate from the pack and adhere to the surface.

Then, on Monday, Mass General announced an agreement with Veridex to develop and study a wholly new type of CTC blood test that involves a different, and as yet undisclosed, technology. Media reports issued Monday had erroneously stated that the test involved microchip technology.

Scientists are wagering that these types of test, if successful, might also detect cancer early in its course, predict the odds for a recurrence, and assess a patient's general prognosis.

"There has been speculation that these [stray] cells are the ones that are responsible for the spreading of the disease," said one expert, Dr. Massimo Cristofanilli, professor and chairman of medical oncology at Fox Chase Cancer Center in Philadelphia. "Simple enumeration tells us that this patient has a worse prognosis . . . Now the question is, what other information we can gather, if we are able to capture these cells? For example, could we do gene analysis profiling and can we get information for the best treatment?"

As it stands today, biopsy -- an invasive and sometimes even hazardous procedure -- is one of the few ways doctors can get key information about a cancer's size and characteristics.

"Many people consider [the new blood test to be] a 'liquid biopsy,' so that eventually we can access cancer cells that are representative of the tumor without performing an invasive biopsy," said Cristofanilli, who is not involved in developing the test.

Experts stressed that the new type of test, if it ever arises, may still be years away, and researchers still aren't sure what these circulating tumor cells (CTCs) actually mean.

"They may be able to detect small amounts of cancer cells but we don't know the significance of that. We may be detecting things that don't have clinical significance," explained Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

And as Cristofanilli pointed out, these plans so far are "only for research. The test is not available for clinical use." Later this year, in fact, four major cancer centers -- Mass General, Memorial Sloan-Kettering Cancer Center in New York City, the University of Texas' M.D. Anderson Cancer Center in Houston, and the Dana-Farber Cancer Institute in Boston -- will begin studies using the latest microchip-based CTC test developed by Mass General.

Any such test would need to be developed "along with the process of new drug development and new targeted therapies so we can better use the information with a clinical purpose," Cristofanilli added.

More information

There's more on cancer's spread at the U.S. National Cancer Institute.

SOURCES: Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health System, Baton Rouge, Louisiana; Massimo Cristofanilli, M.D., professor and chairman, department of medical oncology, Fox Chase Cancer Center, Philadelphia; Jan 3, 2011 Associated Press

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Scientists Aim for Test That Could Spot Single Cancer Cell in Blood
2. Scientists Spot DNA Linked With Dangerous Heart Rhythms
3. Ion channel responsible for pain identified by UB neuroscientists
4. Scientists decode secrets of a very common virus that can cause cancer
5. Scientists Spot Genetic Areas Key to Embryonic Development
6. UNC scientists discover potential strategy to improve cancer vaccines
7. Scientists Raise Fat-Burning Levels in Mice
8. Scripps Research scientists awarded $2.35 million to study new obesity treatment
9. NIH scientists identify mechanism responsible for spreading biofilm infections
10. Scientists Find Protein That May Help Control Prostate Cancer
11. UCLA scientists discover mechanism that turns healthy cells into prostate cancer cells
Post Your Comments:
Related Image:
Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... The McHenry ... a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. ... v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... in both surgical and non-surgical treatments, announced the expansion of his private practice ... Surgery. , Highly trained and nationally recognized for his natural approach, Dr. ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology: